Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult Clinical Trial

Official title:

Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05001828
• Other study ID #: POLARIS2020-002
• Status: Recruiting
• Phase: Phase 1
• Start date: April 5, 2022
• Est. completion date: December 2025

Study information

• Verified date: May 2023
• Source: Polaris Group
• Contact: Nicole DeFord
• Phone: 619-808-5065
• Email: ndeford[@]polarispharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.

Description:

This is an open label, single arm, phase 1 trial with recommended phase 2 dose (RP2D) cohorts based on subject inclusion criteria. Lead In: 6 patients will be enrolled to be treated with standard dose of azacitidine and venetoclax and the expected RP2D of ADI-PEG 20 (dose level 0). In case of DLT occurring in >1 patient in cycle 1, 6 additional patients will be accrued at dose level -1 of ADI-PEG 20 while keeping the doses of azacitidine and venetoclax unchanged (Dose level -1). Enrollment to cohort 1 and 2 will start after ≤1 patient out of 6 encounters DLT in cycle 1 at one of these dose levels. The 6 patients enrolled at that dose level will be counted for efficacy analysis in Cohort 1. Cohort 1: Relapsed or refractory AML: target response 25%. Historical expectation for venetoclax and azacitidine is 15%. Cohort 2: Newly diagnosed high risk AML: Target response 55%. Historical expectation for venetoclax and azacitidine is 40%. Treatment may be continued for a total of 24 cycles, each of 28 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Cohort 1: Previously treated (relapsed/recurrent) or refractory AML based on the 2016 revision to the World Health Organization (WHO) criteria (Arber 2016)
• Cohort 2: Untreated AML per 2016 WHO (Arber 2016) criteria with high-risk features and not a candidate for intensive chemotherapy because of age 60 years or older, age-related comorbidities, cardiac disease, prior anthracycline use, high probability of treatment-related mortality, or otherwise would not benefit from intensive chemotherapy treatment.
• Age = 18 years
• Life expectancy reasonably adequate for evaluating the treatment
• White blood cell (WBC) count of 10 × 109/L or less. (Use of hydroxyurea to control WBC is allowed till 48 hours prior to protocol treatment)
• Adequate renal function: Creatinine = 1.5 x upper limit of normal (ULN) or creatinine clearance > 40 mL/minute (measured or calculated according to the Cockcroft-Gault formula)
• Adequate liver function
• Total bilirubin = 1.5 x ULN
• ALT and AST both = 2.5 x institutional ULN or = 5 times the ULN for patients with leukemic involvement of liver

Exclusion Criteria:

• Prior treatments as follows:

1. Cohort 1: >2 cycles of prior combination treatment with venetoclax+hypomethelating agent (i.e. azacitidine, decitabine) is exclusionary. All other prior treatment for antecedent hematological disorders and/or for AML is permitted.

2. Cohort 2: Prior treatment for antecedent hematological disorders with venetoclax or chemotherapy or any prior treatment for their AML is exclusionary. However, treatment with other agents, including hydroxyurea or =2 cycles of hypomethylating agent (i.e. azacitidine, decitabine), for MDS or myeloproliferative neoplasm is permitted.

• Cohort 2: Favorable risk AML per European LeukemiaNet (ELN) 2022 criteria (Döhner 2022)
• Known active CNS involvement by leukemia

Related Conditions & MeSH terms

• Acute Myeloid Leukemia, Adult
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• ADI-PEG 20
ADI-PEG 20 in combination with venetoclax and azacitidine

Locations

Country	Name	City	State
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	MD Anderson Cancer Center	Houston	Texas
United States	Orchard Healthcare Research Inc	Skokie	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Polaris Group

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the RP2D of ADI-PEG 20 in combination with venetoclax and azacitidine, per the number of subjects with treatment-related adverse events by current CTCAE		6 months
Secondary	Determine preliminary evidence of tumor activity, per the revised 2017 European LeukemiaNet criteria		2 years
Secondary	Determine the peripheral blood arginine levels of ADI-PEG 20 in combination with venetoclax and azacitidine		2 years
Secondary	Determine the peripheral blood citrulline levels of ADI-PEG 20 in combination with venetoclax and azacitidine		2 years
Secondary	Determine the anti-drug antibodies of ADI-PEG 20 in combination with venetoclax and azacitidine		2 years